Platform

The Amphivena ReSTORE platform provides dual-action biologics that relieve immune suppression and activate T cell effector function in cancer patients.

 

The platform design integrates elements of avidity, target selectivity and enhanced safety within a single molecule.

 

The platform can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing.

Amphivena’s Proprietary ReSTORE Platform Supports Pipeline Expansion

Relieve Suppression of T cells in Oncology and Reinvigorate Effectors

ReSTORE Core Module Key Features

Avidity

Bivalent design enables avid binding to clustered receptors* for potent target cell killing

Selectivity

Avid binding imparts selectivity for target cells* while sparing differentiated myeloid cells

* CD33 actively signals on MDSC, and clusters in lipid rafts

Safety

Enhanced target cell selectivity and T cell activation profile from bivalent target engagement leads to a more manageable safety profile

Portfolio

Our lead candidate, AMV564, is currently in clinical studies in both solid tumor and hematologic cancers

 

We are advancing additional bivalent, multi-target candidates through preclinical development

Pipeline Overview

Amphivena_Pipeline_Overview_900x485-01

Lead Candidate AMV564

AMV564 induces T cell mediated killing of MDSC and drives T cell activation

 

Via bivalent engagement of CD33 and T Cells

AMV564 harnesses the patient’s own T-cells to both relieve immune suppression and restore anti-cancer T cell function systemically and in the tumor microenvironment. AMV564 induces T cell mediated killing of myeloid derived suppressor cells (MDSC) and AML leukemic blasts, while sparing differentiated myeloid cells (e.g., neutrophils and monocytes) and drives activation and
repolarization of T cells and improved T effector function.

 

To date, over 80 patients have received AMV564 across three Phase 1 clinical trials for solid tumors, acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and AMV564 has demonstrated monotherapy activity in solid tumor and hematologic cancer patients with an excellent safety profile as well as combinability with checkpoint inhibition. We are uniquely positioned to leverage the simultaneous relief of immune suppression and enhanced T cell effector function to restore anti-cancer immunity in patients.